Skip to main content

Table 1 Characteristics of the study population, for the “before” and “after” periods, in the reference centre and in the two peripheral centres

From: Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study

  Overall   Reference centre   Peripheral centres  
  Before After p Before After p Before After p
Number 306 361   149 193   157 168  
Age (year) 61.5 ± 12.5 62.3 ± 13.6 0.31 60.0 ± 11.9 60.4 ± 14.1 0.68 62.9 ± 12.9 64.1 ± 12.9 0.30
61 [31–88] 62 [24–89]   61 [31–87] 61 [26–88]   62 [31–88] 64 [24–89]  
Hormone status          
Estrogen receptors    0.40    0.51    0.04
Positive 264 (86.8) 318 (89.1)   131 (89.1) 164 (86.3)   133 (84.7) 154 (92.2)  
Negative 40 (13.2) 39 (10.9)   16 (10.9) 26 (13.7)   24 (15.3) 13 (7.8)  
Progesterone receptors    0.06    0.27    0.14
Positive 230 (75.7) 292 (81.8)   113 (76.9) 156 (82.1)   117 (74.5) 136 (81.5)  
Negative 74 (24.3) 65 (18.2)   34 (23.1) 34 (17.9)   40 (25.5) 31 (18.6)  
All negative receptors    0.39    0.61    0.03
Yes 38 (12.5) 36 (10.1)   15 (10.2) 24 (12.6)   23 (14.7) 12 (7.2)  
No 266 (87.5) 321 (89.9)   132 (89.8) 166 (87.4)   134 (85.4) 155 (92.8)  
SBR grade    0.43    0.05    0.62
1 84 (28.3) 112 (31.8)   40 (28.4) 64 (34.2)   44 (28.2) 48 (29.1)  
2 162 (54.6) 174 (49.4)   81 (57.5) 83 (44.4)   81 (51.9) 91 (55.1)  
3 51 (17.2) 66 (18.8)   20 (14.2) 40 (21.4)   31 (19.9) 26 (15.8)  
Tumor size (mm) 21.1 ± 16.0 20.8 ± 15.6 0.97 20.2 ± 15.2 21.4 ± 15.9 0.39 21.8 ± 16.8 20.0 ± 15.3 0.32
16 [1–82] 15 [1–90]   15 [1–82] 16 [1–90]   17 [1–80] 15 [3–90]  
TNM classification          
T (mm)    0.92    0.24    0.46
0 to 19 189 (63.6) 232 (65.0)   92 (63.0) 122 (63.9)   97 (64.2) 110 (66.3)  
20 to 9 87 (29.3) 101 (28.3)   46 (31.5) 54 (28.3)   41 (27.1) 47 (28.3)  
≥ 50 14 (4.7) 18 (5.0)   5 (3.4) 14 (7.3)   9 (6.0) 4 (2.4)  
All size with extension 7 (2.4) 6 (1.7)   3 (2.1) 1 (0.5)   4 (2.7) 5 (3.0)  
N    0.05    0.03    0.62
0 195 (62.3) 244 (69.1)   95 (63.8) 134 (70.9)   100 (64.9) 110 (67.1)  
1 to 3 81 (27.7) 90 (25.5)   41 (27.5) 45 (23.8)   40 (26.0) 45 (27.4)  
4 to 9 25 (9.4) 13 (3.7)   13 (8.7) 6 (3.2)   12 (7.8) 7 (4.3)  
≥ 10 2 (0.6) 6 (1.7)   0 (0.0) 4 (2.1)   2 (1.3) 2 (1.2)  
Ten-year risk of progression based on AdjuvantOnline score (%)    0.92    0.37    0.69
≤ 20 82 (29.6) 94 (29.4)   29 (21.8) 45 (26.0)   53 (36.8) 49 (33.3)  
]20-40] 110 (39.7) 123 (38.4)   62 (46.6) 67 (38.7)   48 (33.3) 56 (38.1)  
> 40 85 (30.7) 103 (32.2)   42 (31.6) 61 (35.3)   43 (29.9) 42 (28.6)  
\